mRNA Cancer Vaccine Breakthrough For Melanoma

What happened

The outlets' own sentences, most widely reported first. Hover or tap one to see who reported it.

Analysis

How it changed

1. 22 Oct

   WASHINGTON (AP) — A first-of-its-kind cancer vaccine is significantly reducing the chances that melanoma patients’ tumors come back, according to results of a major study released Thursday by drugmakers Moderna and Merck.

   7 outlets · Toronto Star
2. 23 Oct

   Intismeran, developed jointly by Moderna and Merck, represents a new way to harness the immune system in cancer, by training immune cells to recognize 34 specific proteins on tumor cells.

   2 outlets · Time

Coverage 8 articles

• 23 Oct A novel mRNA cancer vaccine helps cut the chances of melanoma tumor recurrence in major studyModerna and Merck released results from a major study showing their mRNA-based personalized cancer vaccine, intismeran, significantly reduces the risk of melanoma recurrence by 42% when used in conjunction with an existing treatment. The vaccine is tailored to each patient based on unique genetic mutations found in their tumor, leveraging mRNA technology similar to that used in COVID-19 vaccines. Dr. Hussein Tawbi…CBC
• 23 Oct World’s first mRNA cancer jab for melanoma cuts risk of death by 42%A large trial has shown that a personalized mRNA cancer vaccine for melanoma reduces the risk of recurrence or death by 42% when used with immunotherapy. The study involved over 1,100 high-risk melanoma patients who had surgery to remove their tumors. This vaccine works by targeting specific markers on each patient’s tumor and activating an immune response against these unique cancer mutations. The combination…Evening Standard
• 23 Oct First personalised cancer vaccine cuts risk of disease returning in major trialA new personalized cancer vaccine, when combined with an existing immunotherapy drug called Keytruda, has shown significant promise in reducing the recurrence and spread of melanoma by 42% and 38%, respectively, over two years. This trial involved more than 1,100 patients who had their tumors surgically removed. The vaccine, named Intismeran, uses mRNA technology similar to that used in some COVID vaccines, tailored…BBC
• 23 Oct Australia at the heart of 'transformational' cancer vaccine breakthroughResearchers led by Australia have developed a world-first cancer vaccine that significantly reduces the risk of melanoma recurrence by 42 percent, according to phase 3 trial results. The study, set to be published in the New England Journal of Medicine, involved 1,137 patients and compared personalized mRNA-based vaccines combined with immunotherapy against immunotherapy alone. The treatment identifies unique…ABC News (AU)
• 23 Oct World-first cancer vaccine slashes death risk in stunning findings led by Aussie scientistProfessor Georgina Long led a world-first cancer vaccine trial that significantly reduced the risk of melanoma recurrence or death by 42% compared to patients treated with only pembrolizumab (Keytruda). The study, involving 1,137 participants across 157 global sites, tested an individualised mRNA vaccine called intismeran, developed by Moderna and MSD. This breakthrough could revolutionize cancer treatment…Daily Mail
• 23 Oct A Personalized Cancer Vaccine Lowers Melanoma Recurrence by 42%Moderna and Merck announced on October 22 that their customized cancer vaccine for late-stage melanoma reduces recurrence or death risk by 42% over two years compared to standard treatment. The study involved more than 1,130 patients who had tumors surgically removed and were then given either the intismeran vaccine (along with Keytruda) or a placebo plus Keytruda. Intismeran uses mRNA technology to help immune…Time
• 22 Oct A novel mRNA cancer vaccine helps reduce the chances of melanoma patients' tumors returningModerna and Merck released results from a major study showing that an mRNA-based cancer vaccine called intismeran significantly reduces by 42% the risk of melanoma returning two years after surgery. The personalized vaccine, which targets unique gene mutations in each patient's tumor, was administered alongside standard post-surgery treatment to over 1,100 people with high-risk melanoma. At the end of the trial, 82%…Toronto Star
• 22 Oct mRNA cancer vaccine slashes melanoma death or recurrence risk by 42%ModernA’s mRNA cancer vaccine combined with Merck's immunotherapy reduced melanoma recurrence or death risk by 42%, according to a Phase 3 clinical trial involving over 1,100 patients. The study also showed a 38% reduction in the spread of cancer and revealed that 82.2% of patients receiving both treatments remained cancer-free after two years compared to 70% for those treated with Keytruda alone. ModernA plans to…The Independent

Keep exploring

Similar coverageMedical Breakthroughs and Reform RecentGlobal Stocks Plunge Over AI Fears After Midterms RecentSpain Train Crash Victims Identified RecentRussian Attacks Raise Death Toll in Ukraine RecentMidterm Elections Results Impact Politics RecentJudge Halts Trump’s Triumphal Arch Construction RecentParaguay President Resigns Amid Banking Crisis RecentRussell Brand Rape Conviction RecentBomb Threats Disrupt European Flights RecentFatal Grizzly Bear Attack in Bella Coola